Bioelectrochemistry Laboratory, Chemical and Pharmaceutical Sciences Faculty, University of Chile, PO Box 233, Santiago 1, Chile.
Bioorg Med Chem Lett. 2011 Jan 15;21(2):812-7. doi: 10.1016/j.bmcl.2010.11.093. Epub 2010 Nov 25.
Nitroimidazole PA-824 is part of an exciting new class of compounds currently undergoing clinical evaluation as novel TB therapeutics. The recently elucidated mechanism of action of PA-824 involves reduction of the nitroimidazole ring and subsequent nitric oxide release. The importance of this compound and its unique activity prompted us to explore how substitution of the nitroimidazole ring would affect electrochemical reduction and antitubercular activity. We prepared analogs of PA-824 with bromo, chloro, cyano, and amino substituents in the 5-position of the aromatic ring. We found that substitution of the imidazole ring greatly influences reduction and the stability of the corresponding nitro radical anion. Further, the antitubercular activities of the bromo and chloro analogs may indicate that an alternate nitroreductase pathway within Mycobacterium tuberculosis exists.
硝咪唑 PA-824 是目前正在进行临床试验的新型结核病治疗药物中令人兴奋的新型化合物的一部分。PA-824 的最近阐明的作用机制涉及硝咪唑环的还原和随后的一氧化氮释放。该化合物的重要性及其独特的活性促使我们探索硝咪唑环的取代如何影响电化学还原和抗结核活性。我们制备了在芳香环的 5 位具有溴、氯、氰基和氨基取代基的 PA-824 类似物。我们发现,咪唑环的取代极大地影响了还原和相应的硝基自由基阴离子的稳定性。此外,溴代和氯代类似物的抗结核活性可能表明结核分枝杆菌中存在替代的硝基还原酶途径。